SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 20)
--------------------
Interneuron Pharmaceuticals, Inc.
-----------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
--------------------------------------------------------
(Title of Class of Securities)
460573108
----------------------------------------------------------
(CUSIP Number)
Nadine Shaoul, D.H. Blair Investment Banking Corp.
44 Wall Street, New York, NY 10005 (212) 495-4163
------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 30, 1997
-----------------------------------------------------------
(Date of Event which Requires FIling of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b) (3) or (4), check the following box [ ].
Check the following box if a fee is being paid with this statement [ ].(A fee
is not required only if the reporting person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 pages
<PAGE>
CUSIP No. 460573108 13D Page 2 of 5 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J. Morton Davis
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 Source of Funds
See Item #3 herein.
- -------------------------------------------------------------------------------
5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 8,965,793
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 8,965,793
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,466,958
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
25.5%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 460573108 13D Page 3 of 5 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
D.H. Blair Investment Banking Corp.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 Source of Funds
See Item #3 herein.
- -------------------------------------------------------------------------------
5 Check Box if Disclosure of Legal Proceedings is required pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 8,711,337
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
8,711,337
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,711,337
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
21.2%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
BD
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
Page 4 of 5 Pages
J. Morton Davis and D.H. Blair Investment Banking Corp.
("Blair Investment"), (together, the "Reporting Parties") hereby
amend the following items in their statement on Schedule 13D relating
to the common stock, $.001 par value ("shares") of Interneuron
Pharmaceuticals, Inc. (the "Issuer") as follows:
Item 3. is hereby amended by adding the following new paragraphs thereto:
Since the previously filed Schedule 13D, Amendment No. 19, dated
May 1, 1996, Blair Investment used its general funds to purchase
1,800 shares for a total purchase price of $26,550.00.
Since the previously filed Schedule 13D, Amendment No. 19, Rivkalex
Corporation (1) used its general funds to purchase 20,000 shares at
a total purchase price of $379,316.63.
Since the previously filed Schedule 13D, Amendment No. 19,
Rosalind Davidowitz used her personal funds to purchase an additional
1,800 shares at a total purchase price of $23,657.63
Since the previously filed Schedule 13D, Amendment No. 19, Engex,
Inc. (2) used its general funds to purchase 3,600 shares at a total
purchase price of $139,050.00.
Item 4. is hereby partially amended by deleting the first sentence and
substituting the following sentence therein:
This Amendment is filed solely to report that Blair Investment
has gifted a total of 600,000 shares to charitable foundations.
Item 5. (a) is hereby amended in its entirety as follows:
As of December 30, 1997, Mr. Davis may be deemed to beneficially
own 10,466,958 shares or 25.5% of the Issuer's shares issued and
outstanding as follows: (i) 6,956 shares owned directly by Mr. Davis,
(ii) 8,711,337 shares owned by Blair Investment, (iii) 247,500 shares
owned by Engex,(iv) 323,300 shares owned by Rosalind Davidowitz,
Mr. Davis' wife, (v) 677,865 shares owned by Rivkalex Corporation, and
(vi) 500,000 shares held in the J. Morton Davis Retirement Annuity
Trust ("the "Trust") of which Rosalind Davidowitz is trustee.
As of December 30, 1997, Blair Investment may be deemed to
beneficially own 8,711,337 shares or 21.2% of the Issuer's shares
issued and outstanding as indicated in (ii) above.
Item 5. (b) is hereby amended in its entirety as follows:
Mr. Davis has sole power to vote or to direct the vote, to
dispose or to direct the disposition of those shares owned directly by
him and those owned by Blair Investment. Rosalind Davidowitz has sole
power to dispose or to direct the disposition of those shares owned
directly by her, those owned by Rivkalex Corporation, and those held
in the Trust. Voting and dispositive decisions regarding shares owned
by Engex are made by Mr. Davis as Chairman of the Board of Engex.
Item 5. (c) is hereby amended by adding the following paragraph thereto:
On December 30, 1997, Blair Investment made gifts of 300,000
shares, 100,000 shares, 100,000 shares, and 100,000 shares,
respectively, to each of four charitable foundations. No other
transactions were made in the Issuer's shares by the Reporting Parties
in the previous sixty days.
_________________________________________________________________________
(1) Rivkalex Corporation ("Rivkalex") is a private corporation owned by
Rosalind Davidowitz. Filing of this statement shall not be deemed an admission
by J. Morton Davis that he beneficially owns the securities attributed to
Rivkalex, the Trust, or Rosalind Davidowitz for any purpose. J. Morton Davis
expressly disclaims beneficial ownership of all securities held by Rivkalex, the
Trust, or Rosalind Davidowitz for any purpose.
(2) Engex, Inc. ("Engex") is an investment company registered under Section
8 of the Investment Company Act. Mr. Davis is reporting as a beneficial owner of
the securities owned by Engex because of his role as investment advisor to
Engex. Filing of this statement shall not be deemed an admission by J. Morton
Davis that he beneficially owns the securities attributed to Engex for any
purpose. J. Morton Davis expressly disclaims beneficial ownership of all
securities held by Engex for any purpose.
<PAGE>
Page 5 of 5 pages
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, we
certify that the information set forth in this statement is true, complete
and correct.
/s/ J. Morton Davis
Date: January 5, 1998 _____________________________
New York, New York J. Morton Davis
D.H. BLAIR INVESTMENT BANKING CORP.
/s/ David Nachamie
Date: January 5, 1998 by_____________________________
New York, New York David Nachamie
Treasurer
